Boron Phenylalanine With or Without Mannitol in Treating Patients With Glioblastoma Multiforme - Trial NCT01233492
Access comprehensive clinical trial information for NCT01233492 through Pure Global AI's free database. This Phase 1 trial is sponsored by Cancer Research UK and is currently Terminated. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 36 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Cancer Research UK
Timeline & Enrollment
Phase 1
Oct 01, 2007
Sep 01, 2013
Primary Outcome
Optimal dose of boron phenylalanine (BPA),Causality of each adverse event to BPA and grading severity according to NCI CTCAE Version 3.0,Pharmacokinetic (PK) parameters used to construct a PK model with the aim of being able to predict boron up-take by tumor and normal brain tissue
Summary
RATIONALE: Giving boron phenylalanine in different ways and measuring it in tissue in
 patients with glioblastoma multiforme may help in planning better radiation therapy, such as
 boron neutron capture therapy, for patients in the future.
 
 PURPOSE: This phase I trial is studying the side effects, best dose boron phenylalanine, and
 best way of giving it with or without mannitol in treating patients with glioblastoma
 multiforme.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01233492
Non-Device Trial